Results 231 to 240 of about 8,290,554 (306)

Aquaporin‐3 and aquaporin‐5 impact the development of pancreatic ductal adenocarcinoma spheroids

FEBS Open Bio, EarlyView.
Schematic representation of the role of aquaporin‐3 (AQP3) and aquaporin‐5 (AQP5) in pancreatic ductal adenocarcinoma (PDAC). Both proteins are upregulated in PDAC and are associated with tumor progression and metastatic potential. Silencing AQP3 or AQP5 in PDAC spheroids results in decreased diameter, area, and overall growth, underscoring their key ...
Catarina Pimpão, Diogo M. Engrácia, Graça Soveral, Filipa Mendes   +3 more
wiley   +1 more source

Comment on "Association of Body Mass Index With SARS-CoV-2 Infection in Inflammatory Arthritis Patients Receiving Biologic Therapy: Singapore National Biologics Register Findings". [PDF]

Int J Rheum Dis
Kumar S, Gupta N, Singh SK, Srinivasan H, Vadhithala V.   +4 more
europepmc   +1 more source

Loss of AMBRA1 activates MAPK and angiogenesis signaling pathways in melanoma cells

FEBS Open Bio, EarlyView.
Loss of AMBRA1 in melanoma cells activates multiple oncogenic pathways associated with tumor progression. Transcriptomic and protein network analyses revealed that AMBRA1 depletion enhances MAPK/ERK signaling, angiogenesis, TGF‐β/EMT signaling, and Wnt/axon guidance pathways.
Milad Ibrahim, Marco Corazzari, Iman Osman, Jane Armstrong, Noel Carter   +4 more
wiley   +1 more source

From skin clearance to psychological wellbeing: real-world outcomes of biologic therapy in psoriasis. [PDF]

Front Psychol
Cuniberti F, Miniotti M, Bailon M, Mastorino L, Ortoncelli M, Picardi A, Ribero S, Leombruni P.   +7 more
europepmc   +1 more source

Beyond biomarkers: the role of clinical factors associated with biologic therapy response in severe asthma. [PDF]

Ann Med
Lopez-Rodríguez R, Cañas JA, Mahíllo-Fernández I, Rial MJ.   +3 more
europepmc   +1 more source

Addressing the gaps in biologic therapy utilization trends in IBD from Saudi Arabia. [PDF]

Saudi J Gastroenterol
Alhashimalsayed Z.
europepmc   +1 more source

Impact of 5-Aminosalicylic acid discontinuation in children with ulcerative colitis on biologic therapy: A propensity score-matched study. [PDF]

J Pediatr Gastroenterol Nutr
D'Arcangelo G, Scarallo L, Mancuso G, Corpino M, Romano C, Norsa L, Arrigo S, Bramuzzo M, Fioretti MT, Zuin G, Illiceto MT, Lionetti P, Aloi M.   +12 more
europepmc   +1 more source

Global prevalence of eligibility for biologic therapy in ATS/ERS-defined severe asthma: A systematic review. [PDF]

World Allergy Organ J
Yang F, Salciccioli JD, Patel RE, McClean M, Bloom CI.   +4 more
europepmc   +1 more source

How to Choose the Biologic Therapy in a Bio-naïve Patient with Inflammatory Bowel Disease

Journal of Clinical Medicine, 2022
The availability of biologic therapies in inflammatory bowel disease (IBD) is increasing significantly. This represents more options to treat patients, but also more difficulties in choosing the therapies, especially in the context of bio-naïve patients.
Viviana Laredo, Carla J Gargallo, Fernando Gomollón   +2 more
exaly   +2 more sources

Lower incidence of COVID‐19 in patients with inflammatory bowel disease treated with non‐gut selective biologic therapy

Journal of Gastroenterology and Hepatology (Australia), 2021
Since the outbreak of COVID‐19, concerns have been raised as to whether inflammatory bowel disease (IBD) patients under biologic therapy may be more susceptible to the disease.
Simone Saibeni, Sandro Ardizzone, Antonio di Sabatino   +2 more
exaly   +2 more sources